× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine

face mask

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs

sodium aescinate

Apilimod

corticosteroids 7

ciclesonide

dexamethasone 1

inhaled steroids

low-dose corticosteroids

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

BCG vaccination

Immunosuppressants drugs

anakinra

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab 1

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 1

azvudine

baloxavir marboxil

carrimycin

chloroquine and derivatives 4

chloroquine 1

hydroxychloroquine 12

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

fluvoxamine

hydroxychloroquine plus macrolides 5

interferon

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 3

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 2

Renin-angiotensin-system-acting agents 7

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

levamisole

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

prone positioning

PUL-042 inhalation solution

selinexor

stem cells

tradipitant

tranilast

Latest studies

RECOVERY , 2020   3 days ago

lopinavir/ritonavir vs. control high risk of bias

    the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm

  • inconclusive results for: 28-day mortality

the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm

meta-analysis

Arshad (HCQ) , 2020   OBS 5 days ago

hydroxychloroquine vs. control critical risk of bias

  • suggested 66 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

Arshad (HCQ AZ) , 2020   OBS 5 days ago

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • suggested 71 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

Lagier , 2020   OBS 2 weeks ago

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • suggested 70 % decrease in death, ICU transfer, hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias
  • suggested 51 % decrease in mortality but with a very low degree of certainty due to critical risk of bias
  • suggested 62 % decrease in hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias

meta-analysis

Sbidian (HCQ alone) , 2020   OBS 3 weeks ago

hydroxychloroquine vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

RECOVERY dexamethasone unpublished   NCT04381936 3 weeks ago

dexamethasone vs. standard of care NA risk of bias

  • demonstrated 17 % decrease in death

in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)

meta-analysis

RECOVERY unpublished   NCT04381936 5 weeks ago

hydroxychloroquine vs. control NA risk of bias

  • inconclusive results for: 28-day death

meta-analysis

Boulware , 2020   NCT04308668 5 weeks ago

hydroxychloroquine vs. placebo low risk of bias

  • inconclusive results for: death; incidence of new illness compatible with Covid-19; hospitalization

meta-analysis

NIH NIAID ACTT-1 , 2020   NCT04280705 2 months ago

remdesevir vs. placebo some concern in risk of bias

  • suggested 32 % increase in recovery
  • suggested 28 % decrease in serious adverse events
  • inconclusive results for: death

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons